TIPE2, a negative regulator of TLR signaling, regulates p27 through IRF4-induced signaling

Peng,Yanping; Zhao,Qian; Zhang,Hanyu; Han,Bo; Liu,Suxia; Han,Mingyong; Liu,Shili

doi:10.3892/or.2016.4562

TIPE2, a negative regulator of TLR signaling, regulates p27 through IRF4-induced signaling

Authors:
- Yanping Peng
- Qian Zhao
- Hanyu Zhang
- Bo Han
- Suxia Liu
- Mingyong Han
- Shili Liu
View Affiliations

Affiliations: School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: January 14, 2016 https://doi.org/10.3892/or.2016.4562
Pages: 2480-2486

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Targeted inhibition of specific toll-like receptor (TLR) pathways may provide an effective strategy to prevent the development of selected gastric malignancies. Tumor necrosis factor (TNF)-α-induced protein 8-like-2 (TIPE2) was identified as a novel negative regulator of TLR signaling. Our previous study identified TIPE2 as an inhibitor of gastric cancer cell growth; it promotes p27 expression, which leads to restored control of the cell cycle and cell division. However, the molecular mechanism by which TIPE2 regulates p27 remains unclear. In the present study, we examined the expression patterns of TIPE2 in serial clinical gastritis tissues as well as gastric cancer, and found a negative correlation between TIPE2 expression and progression of gastritis to gastric cancer. This negative correlation verified the role of TIPE2 in preventing the occurrence and development of gastric cancer, suggesting that TIPE2 may be a potential biomarker for gastric cancer progression. To determine the mechanism employed by TIPE2 in gastric cell carcinogenesis, a TIPE2-expressing plasmid was introduced into gastric cell lines, and microarray and western blot analysis revealed that TIPE2 selectively upregulates the expression of interferon regulatory factor 4 (IRF4). Variations in IRF4 expression were additionally verified in knockout mice. Next, the effect of IRF4 on p27 expression was tested by an IRF4 siRNA interference assay. Finally, we explored the signaling pathways used by TIPE2 to regulate IRF4. An experiment using pathway inhibitors and a nuclear factor κ-light-chain enhancer of activated B cells (NF-κB) luciferase reporter assay showed that NF-κB plays a crucial role in regulating IRF4 expression. Our data provide evidence that TIPE2, a potential biomarker for gastric cancer progression, stimulates an IRF4-associated signaling cascade that promotes p27 expression and controls cell growth. To the best of our knowledge, this is the first study to demonstrate that IRF4 acts as an inhibitor of epithelial cell proliferation and mediates the expression of TIPE2, a negative regulator of TLR signaling, to control cell growth.

View Figures

View References

1	Yang L, Parkin DM, Li LD, Chen YD and Bray F: Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer. 90:2157–2166. 2004.PubMed/NCBI
2	Yang L, Parkin DM, Ferlay J, Li L and Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 14:243–250. 2005.PubMed/NCBI
3	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5(Suppl 1): S5–S11. 2002. View Article : Google Scholar
4	Fukata M and Abreu MT: Role of Toll-like receptors in gastrointestinal malignancies. Oncogene. 27:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
5	Whitehead R, Truelove SC and Gear MW: The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens. J Clin Pathol. 25:1–11. 1972. View Article : Google Scholar : PubMed/NCBI
6	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
7	Liew FY, Xu D, Brint EK and O'Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 5:446–458. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kondo T, Kawai T and Akira S: Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol. 33:449–458. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, et al: TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 133:415–426. 2008. View Article : Google Scholar : PubMed/NCBI
10	Li D, Song L, Fan Y, Li X, Li Y, Chen J, Zhu F, Guo C, Shi Y and Zhang L: Down-regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol. 133:422–427. 2009. View Article : Google Scholar : PubMed/NCBI
11	Zhang G, Hao C, Lou Y, Xi W, Wang X, Wang Y, Qu Z, Guo C, Chen Y and Zhang Y: Tissue-specific expression of TIPE2 provides insights into its function. Mol Immunol. 47:2435–2442. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhang L, Shi Y, Wang Y, Zhu F, Wang Q, Ma C, Chen YH and Zhang L: The unique expression profile of human TIPE2 suggests new functions beyond its role in immune regulation. Mol Immunol. 48:1209–1215. 2011. View Article : Google Scholar : PubMed/NCBI
13	Xi W, Hu Y, Liu Y, Zhang J, Wang L, Lou Y, Qu Z, Cui J, Zhang G, Liang X, et al: Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Mol Immunol. 48:1203–1208. 2011. View Article : Google Scholar : PubMed/NCBI
14	Kong L, Liu K, Zhang Y-Z, Jin M, Wu BR, Wang WZ, Li W, Nan YM and Chen YH: Downregulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with chronic hepatitis C. Hepatol Int. 7:844–849. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhao Q, Zhao M, Dong T, Zhou C, Peng Y, Zhou X, Fan B, Ma W, Han M and Liu S: Tumor necrosis factor-α-induced protein-8 like-2 (TIPE2) upregulates p27 to decrease gastic cancer cell proliferation. J Cell Biochem. 116:1121–1129. 2015. View Article : Google Scholar
16	Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K, Matsuyama T, Taniguchi T and Honda K: Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci USA. 102:15989–15994. 2005. View Article : Google Scholar : PubMed/NCBI
17	Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS and Lu R: IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One. 6:e226282011. View Article : Google Scholar : PubMed/NCBI
18	Fanzo JC, Hu CM, Jang SY and Pernis AB: Regulation of lymphocyte apoptosis by interferon regulatory factor 4 (IRF-4). J Exp Med. 197:303–314. 2003. View Article : Google Scholar : PubMed/NCBI
19	Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL and McCarty KS Jr: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 46:5419–5425. 1986.PubMed/NCBI
20	Wang H, Sun Y, Liu S, Yu H, Li W, Zeng J, Chen C and Jia J: Upregulation of progranulin by Helicobacter pylori in human gastric epithelial cells via p38MAPK and MEK1/2 signaling pathway: Role in epithelial cell proliferation and migration. FEMS Immunol Med Microbiol. 63:82–92. 2011. View Article : Google Scholar : PubMed/NCBI
21	Hartwell LH and Kastan MB: Cell cycle control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
22	Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:241–250. 1999. View Article : Google Scholar : PubMed/NCBI
23	Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
24	Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol. 29(Suppl 16): S10–S14. 2002. View Article : Google Scholar
25	Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
26	Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L and Chen YH: The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell. 45:610–618. 2012. View Article : Google Scholar : PubMed/NCBI
27	Lu R: Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol. 29:487–492. 2008. View Article : Google Scholar : PubMed/NCBI
28	Marecki S and Fenton MJ: The role of IRF-4 in transcriptional regulation. J Interferon Cytokine Res. 22:121–133. 2002. View Article : Google Scholar : PubMed/NCBI
29	Jo SH and Ren R: IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner. J Biol Chem. 287:1770–1778. 2012. View Article : Google Scholar :
30	Wang WL, Liu W, Gong HY, Hong JR, Lin CC and Wu JL: Activation of cytokine expression occurs through the TNFα/NF-κB-mediated pathway in birnavirus-infected cells. Fish Shellfish Immunol. 31:10–21. 2011. View Article : Google Scholar : PubMed/NCBI
31	Grumont RJ and Gerondakis S: Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: Modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med. 191:1281–1292. 2000. View Article : Google Scholar : PubMed/NCBI
32	Sharma S, Mamane Y, Grandvaux N, Bartlett J, Petropoulos L, Lin R and Hiscott J: Activation and regulation of interferon regulatory factor 4 in HTLV type 1-infected T lymphocytes. AIDS Res Hum Retroviruses. 16:1613–1622. 2000. View Article : Google Scholar : PubMed/NCBI